Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt- (GASPACCO)

Single-center Randomized Study Evaluating of Oncological Benifits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With Locally Advanced Gastric Cancer in Patients With Cyt-.

Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients. The most common type of tumor progression of this localization is peritoneal carcinomatosis. When peritoneal carcinomatosis occurs, the median survival of patients does not exceed 3 months, the overall survival is no more than 6 months. Unfortunately, when peritoneal carcinomatosis occurs, palliative chemotherapy remains the only treatment option. The modern strategy for the prevention and treatment of peritoneal carcinomatosis is based on the concept of regional chemotherapy. The main methods of regional chemotherapy are hyperthermic intraperitoneal chemotherapy (HIPEC) and Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC). PIPAC is a new technology for delivering chemotherapy drugs to tumor nodes on the surface of the peritoneum and allows the cytostatic to be evenly distributed over the abdominal cavity, increasing the depth of its penetration into tumor nodes due to the properties of aerosol and gradients of intra-abdominal and interstitial pressure. The method has a number of advantages over the HIPEC method: a large penetration depth of drugs, low trauma, the possibility of repeated use. We offer PIPAC for patients with locally advanced gastric cancer and a high risk of developing peritoneal carcinomatosis in an adjuvant mode in addition to standard treatment to prevent the development of carcinomatosis.

Study Overview

• Status: Recruiting
• Conditions: Gastric Cancer; Peritoneal Carcinomatosis
• Intervention / Treatment: Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Docetaxel; Procedure: Staging laparoscopy; Procedure: Radical surgery; Procedure: PIPAC; Drug: Adjuvant chemotherapy

Detailed Description

The study is interventional: patients over 18 years of age with an established diagnosis of stomach cancer (c)T3-4N0-3M0 CYT- will be randomized into 2 groups using the envelope method. The control group will receive only neoadjuvant chemotherapy + gastrectomy/ distal subtotal resection with D2 lymph node dissection, the active comparison group - neoadjuvant chemotherapy + gastrectomy with D2 lymph node dissection + PIPAC (Cisplatin (7.5 mg / m²) + Doxirubicin 1.5 mg / m2)). Will be assessed: overall survival, median survival, disease-free survival, quality of life of patients.

• Study Type: Interventional
• Enrollment (Anticipated): 304
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Alexander Zakharenko, PhD; Phone Number: +7 9219516183; Email: 9516183@mail.ru
• Study Contact Backup: Name: Michael Belyaev, PhD; Phone Number: +7 89218628926; Email: 8628926@mail.ru

Study Locations

• Russian Federation
  • Saint-Petersburg, Russian Federation, 197101
    • Recruiting
    • First Pavlov State Medical University of St. Petersburg
    • Contact: Ilya Vervekin; Phone Number: 89119695285; Email: iivervekin@yandex.ru
    • Sub-Investigator: Michael Belyaev, PhD
    • Principal Investigator: Alexander Zakharenko, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically confirmed, medically operable, resectable stomach adenocarcinoma (cT3-4, any N category, M0).
• No preceding cytotoxic or targeted therapy.
• No prior partial or complete tumor resection.

• Female and male patient ≥ 18 and ≤ 75 years. Female patient with childbearing potential needs to have a negative pregnancy test within 7 days prior to study start. Males and females of reproductive potential must agree to practice highly effective contraceptive measures* during the study. Male patients must also agree to refrain from father a child during treatment and additionally to use a condom during treatment period. Their female partner of childbearing potential must also agree to use an adequate contraceptive measure.

  *highly effective (i.e. failure rate of <1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments).

• ECOG = 0-2.
• Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax, bone scan or MRI (if bone metastases are suspected due to clinical signs). Exclusion of the infiltration of any adjacent organs or structures by CT or MRI.
• Laparoscopic exclusion of peritoneal carcinomatosis at initial staging, before start of FLOT chemotherapy
• Adequate hematological, hepatic and renal function parameters:

Leukocytes ≥ 3000/mm³, platelets ≥ 100,000/mm³, neutrophil count (ANC) ≥1000/µL Serum creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.0 x upper limit of normal, alkaline phosphatase ≤ 6 x upper limit of normal For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN; for patients receiving therapeutic anticoagulation: stable anticoagulant regimen.

• Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures.

Exclusion Criteria:

• Patient without neoadjuvant therapy or those who received a neoadjuvant therapy other than FLOT.
• Known hypersensitivity against 5-FU, leucovorin, oxaliplatin, or docetaxel.
• Other known contraindications against, 5-FU, leucovorin, oxaliplatin, or docetaxel.
• Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV.
• Clinically significant valvular defect.
• Criteria of primary unresectability, e.g.:

Radiologically documented evidence of major blood vessel invasion or invasion of adjacent organs (T4b).

Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastases!).

• Other severe internal disease or acute infection.
• Peripheral polyneuropathy ≥ NCI Grade II.
• Patient has undergone major surgery within 28 days prior to enrollment except staging laparoscopy.
• Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or ascites.
• On-treatment participation in another interventional clinical study in the period 30 days prior to inclusion and during the study.
• Patient pregnant or breast feeding, or planning to become pregnant.
• Any other concurrent antineoplastic treatment including irradiation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PIPAC group; Staging laparoscopy + peritoneal lavage.; 4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.; Radical gastrectomy with D2 - lymph node dissection.; Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².; Adjuvant chemotherapy according to indications.	Drug: 5-Fluorouracil; Day 1 q2w: 2600 mg/m² IV over 24 hours; Other Names: 5-FU; Drug: Leucovorin; Day 1 q2w: 200 mg/m² IV over 30 minutes; Other Names: Calciumfolinat; Drug: Oxaliplatin; Day 1 q2w: 85 mg/m² IV over 2 hours; Drug: Docetaxel; Day 1 q2w: 50 mg/m² IV over 1 hour; Procedure: Staging laparoscopy; All patients undergo staging laparoscopy and peritoneal lavage.; Procedure: Radical surgery; Radical gastrectomy with D2 - lymph node dissection.; Procedure: PIPAC; Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².; Drug: Adjuvant chemotherapy; Adjuvant chemotherapy according to indications.
Active Comparator: Control group; Staging laparoscopy + peritoneal lavage.; 4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.; Radical gastrectomy with D2 - lymph node dissection.; Adjuvant chemotherapy according to indications.	Drug: 5-Fluorouracil; Day 1 q2w: 2600 mg/m² IV over 24 hours; Other Names: 5-FU; Drug: Leucovorin; Day 1 q2w: 200 mg/m² IV over 30 minutes; Other Names: Calciumfolinat; Drug: Oxaliplatin; Day 1 q2w: 85 mg/m² IV over 2 hours; Drug: Docetaxel; Day 1 q2w: 50 mg/m² IV over 1 hour; Procedure: Staging laparoscopy; All patients undergo staging laparoscopy and peritoneal lavage.; Procedure: Radical surgery; Radical gastrectomy with D2 - lymph node dissection.; Drug: Adjuvant chemotherapy; Adjuvant chemotherapy according to indications.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of Overall survival (OS) in both arms	Overall survival (OS) where OS is defined as the time from randomization to death from any cause.	from randomization up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PFS/DFS rates at 2, 3 & 5 years	PFS/DFS rates at 2, 3 & 5 years defined as the percentage of patients without disease progression or relapse after surgery or death from any cause after 2, 3 and 5 years referring to the total number of patients randomized into the respective treatment arm	2, 3 & 5 years after randomization
Rate of surgical serious adverse events (SAEs)	Rate of surgical serious adverse events, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 5.0) grade ≥ 3 adverse events and grade ≥ 3 laboratory toxicities.	After randomization of the patient until 30 days after last study-specific treatment
Patient reported outcomes: Quality of life EORTC QLQ C30 questionnaire	The QoL analyses will include QoL mean values, QoL response and time to symptom deterioration (TTSD) defined as the time interval between randomization and the first decrease by ≥ 10-points. All randomly assigned patients with a baseline and at least one post-baseline assessment will be included in TTSD analyses. Patients without observed deterioration will be censored at the time of their last QoL assessment. Questionnaires given to the patients (validated quality of life questionnaires EORTC QLQ C30). EORTC QLQ C30 contains 30 questions: 28 questions regarding body fitness, daily routines, restrictions at work and hobby, appetite, fatigue, cough, breathlessness, pain, tiredness, and body conditions from (1) to (4); 1 (not a bit), 2 (little), 3 (moderate), 4 (much). 2 questions regarding state of health and Quality of life with a horizontal rating from 1 to 7; 1 (very bad), 7 (excellent).	From date of screening until the date of first documented progression or last visit before date of death from any cause, whichever came first, assessed 8 weeks +/- 7 days until EOT, afterwards every 3 months up to 2 years after last patient in
Patient reported outcomes: VAS pain assessment form	The patient´s assessment of their current level of pain on a 100-mm horizontal VAS. The left-hand extreme of the line should be described as "no pain" and the right-hand as "unbearable pain".	From date of screening until the date of first documented progression or last visit before date of death from any cause, whichever came first, assessed 8 weeks +/- 7 days until EOT, afterwards every 3 months up to 2 years after last patient in
Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification	Rate of post-operative morbidity/mortality will be assessed at day 30 after surgery acc. to Clavien-Dindo classification.	at day 30 after surgery
Comparison of Overall survival rates at 3 and 5 years in both arms	Overall survival rates at 3 & 5 years defined as the percentage patients known to be alive after 3 and 5 years referring to the total number of patients randomized into the respective treatment arm	3 and 5 years after randomization
Comparison of progression-/disease-free survival (PFS/DFS) between arms	PFS/DFS is defined as the time from randomization to disease progression or relapse after surgery or death from any cause.	from randomization up to 5 years
Comparison of peritoneal relapse rate in both arms	Peritoneal relapse rate defined as the percentage of patients with peritoneal relapse referring to the total number of patients randomized into the respective treatment arm	from randomization up to 5 years

Collaborators and Investigators

• Sponsor: St. Petersburg State Pavlov Medical University
• Investigators: Principal Investigator: Alexander Zakharenko, PhD, First Pavlov State Medical University of St. Petersburg; Study Chair: Ilya Vervekin, First Pavlov State Medical University of St. Petersburg

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2020
• Primary Completion (Anticipated): October 10, 2021
• Study Completion (Anticipated): January 10, 2029

Study Registration Dates

• First Submitted: October 15, 2020
• First Submitted That Met QC Criteria: October 15, 2020
• First Posted (Actual): October 22, 2020

Study Record Updates

• Last Update Posted (Actual): November 25, 2020
• Last Update Submitted That Met QC Criteria: November 23, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: Gastric cancer; Peritoneal Carcinomatosis; Intraperitoneal chemotherapy; Aerosol Chemotherapy; Regional Chemotherapy; Peritoneal washings
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Peritoneal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Abdominal Neoplasms; Stomach Neoplasms; Carcinoma; Peritoneal Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Protective Agents; Micronutrients; Vitamins; Antidotes; Vitamin B Complex; Docetaxel; Fluorouracil; Oxaliplatin; Leucovorin
• Other Study ID Numbers: 1-AbOn-2020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No IPD will be shared.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No